lenacapavir (Sunlenca)
Jump to navigation
Jump to search
Indications
- multi-drug resistant HIV1 infection
- combined with other antiretroviral agents
Dosage
- given both orally & by subcutaneous injection every 6 months
Mechanism of action
- HIV1 capsid inhibitor
Notes
- estimated cost $42,250 in the first year of treatment
- therafter $39,000 annually in the subsequent years
More general terms
References
- ↑ Hick L FDA Approves First-in-Class Drug for HIV Medscape. December 22, 2022 https://www.medscape.com/viewarticle/986049